Neuronetics (NASDAQ:STIM) Posts Quarterly Earnings Results, Misses Expectations By $0.07 EPS

Key Points

• Neuronetics reported a quarterly earnings per share (EPS) of ($0.15), missing expectations by ($0.07) EPS, while revenue reached $38.11 million, exceeding analyst estimates.
• The company's stock had a trading volume of 3,270,807 shares, significantly higher than its average of 1,186,601 shares, with a market cap of $308.14 million.
• Insider trading activity included EVP Stephen Furlong selling 193,460 shares, decreasing his ownership stake by 31.71%.

Neuronetics (NASDAQ:STIM - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.07), Zacks reports. Neuronetics had a negative net margin of 43.47% and a negative return on equity of 156.36%. The firm had revenue of $38.11 million during the quarter, compared to analyst estimates of $36.80 million. Neuronetics updated its FY 2025 guidance to EPS and its Q3 2025 guidance to EPS.

Neuronetics Trading Up 3.0%

Shares of STIM stock traded up $0.12 on Friday, reaching $4.13. The company had a trading volume of 1,193,603 shares, compared to its average volume of 1,238,179. The company has a current ratio of 2.02, a quick ratio of 2.28 and a debt-to-equity ratio of 1.76. The stock has a market cap of $273.08 million, a PE ratio of -3.65 and a beta of 1.78. The company has a 50-day moving average of $3.83 and a 200-day moving average of $4.00. Neuronetics has a 12 month low of $0.52 and a 12 month high of $5.92.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group reduced their price target on shares of Neuronetics from $8.00 to $7.00 and set a "buy" rating on the stock in a research report on Wednesday.

Insider Activity at Neuronetics

In related news, EVP Stephen Furlong sold 193,460 shares of the stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $4.27, for a total transaction of $826,074.20. Following the completion of the sale, the executive vice president directly owned 416,593 shares of the company's stock, valued at approximately $1,778,852.11. This represents a 31.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 8.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Neuronetics

A hedge fund recently raised its stake in Neuronetics stock. Geode Capital Management LLC grew its position in shares of Neuronetics, Inc. (NASDAQ:STIM - Free Report) by 172.3% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 879,045 shares of the company's stock after acquiring an additional 556,268 shares during the quarter. Geode Capital Management LLC owned 1.33% of Neuronetics worth $3,068,000 at the end of the most recent reporting period. 53.59% of the stock is owned by hedge funds and other institutional investors.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.